Entera Bio (ENTX) Corporate presentation summary

Mission and strategy

• Focuses on developing transformative, first-in-class oral peptide treatments for underserved therapeutic areas, aiming to drive value for patients, clinicians, and healthcare systems while fostering innovation and resilience.

Technology and platform

• Utilizes proprietary N-Tab® technology to enable oral delivery of large, hydrophilic peptide drugs by inhibiting GI enzymatic degradation and enhancing membrane permeability.

• Platform supports robust protein design and modification, with partnerships such as OPKO expanding development capabilities.

Lead asset: EB613 for osteoporosis

• EB613 is the first once-daily oral PTH (1-34) anabolic tablet for osteoporosis, targeting a $4–6B+ US market with a significant treatment gap, especially among postmenopausal women.

• Phase 2 trials met primary and secondary endpoints, showing significant BMD increases at lumbar spine, femoral neck, and total hip, with a safety profile consistent with PTH agonists.

• Demonstrated comparable or superior efficacy to Forteo® injections, with strong adoption potential across specialties.